DT 9045
Alternative Names: DT-9045Latest Information Update: 16 Jun 2024
At a glance
- Originator Domain Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PAR 2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 26 Mar 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Domain Therapeutics
- 29 Jun 2023 Domain Therapeutics plans a phase I trial for Solid tumours (Recurrent, Metastatic disease), in mid-2025